NCT05055999已完成不适用
Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy
Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
The purpose of the trial is to detect tumor microenvironment on Extensive Stage Small Cell Lung Cancer with simultaneous liver metastases who Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18， Extensive Stage Small Cell Lung Cancer Confirmed by Histopathology Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy
排除标准
- •Patients with contraindication of chemotherapy Pregnant or breast feeding women
结局指标
主要结局
PFS
时间窗: April 2019- July 2021
Progression free survival
OS
时间窗: April 2019- July 2021
Overall survival
次要结局
未报告次要终点
研究者
Yongchang Zhang
Director, Head of Medical Oncology, Principal Investigator, Clinical Professor
Hunan Province Tumor Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to ImmunotherapyLung CancerNCT05636605The Fourth Affiliated Hospital of Zhejiang University School of Medicine200
招募中
不适用
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and ChemotherapyTumor MicroenvironmentImmunotherapyChemotherapyGastric CancerNCT06202781Chinese PLA General Hospital28
Unknown
不适用
Molecular Profiling in Small Cell Lung CancerLung NeoplasmsSmall Cell Lung CancerNCT03162705Zhujiang Hospital120
招募中
不适用
Exploratory biomarker study on tumor microenvironment using pre-treatment and refractory archival samples of hepatocellular carcinomaJPRN-UMIN000047701Chiba University Hospital60
招募中
不适用
Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer PatientsHER2-positive Breast CancerNCT06518382Giampaolo Bianchini10